Nektar Therapeutics is exploring strategic options, including a possible sale of the company, Bloomberg News reported, citing people familiar with the matter.
The pharmaceuticals company is also considering partnerships and licensing deals, according to the publication.
No final decisions have been made and warned that negotiations may not lead to an agreement, the sources said.
